| 0.42 Data as of May 17 |  +0.001 / +0.24%Today’s Change | 0.21 Today|||52-Week Range 0.48 | +44.83% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $56.5M |
Company Description
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company leveraging significant government investment to develop a platform of novel compounds in oncology and biodefense. It is developing a new class of catalytic antioxidant compounds that protects healthy tissue from the damaging effects of radiation. These compounds, known as metalloporphyrins, scavenge reactive oxygen species at the cellular level, mimicking the effect of the body's own natural antioxidant enzyme superoxide dismutase. Its compound, AEOL 10150, is a metalloporphyrin specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure. Aeolus Pharmaceuticals was founded in 1994 and is headquartered in Mission Viejo, CA.
Employees
Shareholders
| Individual stakeholders | 91.38% |
| Mutual fund holders | -- |
| Other institutional | -- |
Top Executives
| John L. McManus | President & Chief Executive Officer |
| Christopher Stanley | Vice President-Operations |
| Russell L. Skibsted, MBA | Chief Financial Officer, Secretary, CAO & SVP |
| Cindy Croissant | Director-Clinical Operations |
| Brian J. Day, PhD | Chief Scientific Officer |
.
